# Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

> **NCT07288814** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-Sen University Cancer Center** · enrollment: 43 (estimated)

## Conditions studied

- Relapsed or Refractory Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome & Enlonstobart

## Key facts

- **NCT ID:** NCT07288814
- **Lead sponsor:** Sun Yat-Sen University Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288814, "Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07288814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*